EQT to buy molecular testing firm Qiagen for $10.8 billion
Swedish private equity firm EQT has reached an agreement to buy molecular testing company Qiagen in a transaction valued at approximately EUR9.6 billion, or about $10.78 billion. The all-cash public takeover offer brings an end to years of takeover speculation surrounding the Dutch diagnostic group. Both companies announced the recommended voluntary agreement on Wednesday. The transaction highlights growing private equity interest in the life sciences sector, where robust demand for molecular testing technologies continues to spur consolidation and dealmaking activity after prior attempts by other suitors failed.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Sweden's EQT will buy molecular testing company Qiagen for about EUR9.6 billion ($10.78 billion).
- ✓ The announcement of the recommended voluntary all-cash public takeover offer was made by Qiagen and EQT Private Equity.
What changed
EQT and Qiagen announced a recommended voluntary all-cash public takeover agreement.
Live updates
-
EQT Agrees to Acquire Molecular Testing Firm Qiagen
Swedish private equity firm EQT has reached an agreement to buy molecular testing company Qiagen in a transaction valued at approximately EUR9.6 billion, or about $10.78 billion. The all-cash public takeover offer brings an end to years of takeover speculation surrounding the Dutch diagnostic group. Both companies announced the recommended voluntary agreement on Wednesday. The transaction highlights growing private equity interest in the life sciences sector, where robust demand for molecular testing technologies continues to spur consolidation and dealmaking activity after prior attempts by other suitors failed.
Why it matters
Qiagen previously slipped out of a potential acquisition grip by Thermo Fisher during the pandemic when holdout investors sank that bid. The new structure from EQT is designed specifically to outvote holdouts. Bank of America has assigned no rating to Qiagen stock amid the buyout process.
What is confirmed
- Sweden's EQT will buy molecular testing company Qiagen for about EUR9.6 billion ($10.78 billion).
- The announcement of the recommended voluntary all-cash public takeover offer was made by Qiagen and EQT Private Equity.
Still unconfirmed
- An entity of EQT agreed to acquire Qiagen for EUR10.8 billion, about $12.1 billion cash.
What to watch next
- Finalization of the acquisition and shareholder acceptance levels regarding the all-cash public takeover offer
- Regulatory approvals and closing timeline for the transaction
confidence 90%Sources used for this update (13)
- help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
- seekingalpha.com — Patient Capital Management Q3 2026 Commentary
- Reuters — EQT to buy molecular testing firm Qiagen for $10.8 billion
- Financial Times — Buyout firm EQT acquires German diagnostics group in €10.8bn deal
- Bloomberg.com — EQT Nears €9.6 Billion Deal for Molecular Testing Firm Qiagen
- Business Wire — QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer
- GuruFocus — Bank of America Assigns No Rating to Qiagen (QGEN) Amid EQT Buyo
- www.martincid.com — EQT’s €10.8bn Qiagen buyout is built to outvote holdouts who sank Thermo Fisher’s bid – Martin Cid Magazine
- www.globalbankingandfinance.com — EQT to Acquire Qiagen in $10.8 Billion Molecular Testing Deal
- ca.marketscreener.com — Buyout firm EQT to acquire Qiagen for $10.8 billion | MarketScreener Canada
- live.euronext.com — EQT to buy molecular testing firm Qiagen for $10.8 billion
- whbl.com — EQT to buy molecular testing firm Qiagen for $10.8 billion
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community